May 20th, 2020

Presentation of “SPI2” Phase III Results at the EAN Virtual Congress 2020
Read more

March 10th, 2020

MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis
Read more

December 12th, 2019

MedDay Reports Last Patient Study Visit in Second Phase 3 Clinical Trial with MD1003®, an Important Milestone Towards Completion of the SPI2 Study in Progressive Multiple Sclerosis
Read more

July 22nd, 2019

MedDay Pharmaceuticals to webcast key opinion leader meeting on new treatment strategies for progressive forms of multiple sclerosis tomorrow
Read more